Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
NCT02254005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2023-10-24
Summary
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Conditions
- Breast Neoplasms
Interventions
- DRUG
-
bivatuzumab mertansine
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-10-01
- Primary Completion
- 2004-12-01
More Related Trials
-
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
NCT00445406 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
NCT05522491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
BMS-247550 in Treating Women With Metastatic Breast Cancer
NCT00020904 ·Status: COMPLETED ·Phase: PHASE2
-
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
NCT00002544 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
NCT00333775 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
NCT00907959 ·Status: UNKNOWN ·Phase: PHASE2
-
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
NCT00232505 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
NCT03577743 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
NCT00448591 ·Status: COMPLETED ·Phase: PHASE3
-
BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
NCT03789019 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
NCT00431067 ·Status: COMPLETED ·Phase: PHASE2
-
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
NCT01097460 ·Status: COMPLETED ·Phase: PHASE1
-
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
NCT01125566 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
NCT00820547 ·Status: COMPLETED ·Phase: PHASE2
-
DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT05901935 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
NCT01004172 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
NCT00070252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
NCT00509769 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
NCT00520975 ·Status: TERMINATED ·Phase: PHASE3
-
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
NCT03624543 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
NCT00288249 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib for Metastatic Triple Negative BrCa
NCT01738438 ·Status: COMPLETED ·Phase: PHASE2
-
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
NCT02783794 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
NCT00281697 ·Status: COMPLETED ·Phase: PHASE3
-
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00045097 ·Status: COMPLETED ·Phase: PHASE2